Blue Jet Healthcare Share Price Target 2026, 2027, 2030, 2040, 2050
Blue Jet Healthcare is a global company that makes special chemicals needed to create different medicines. It works as a CDMO, which means it helps other pharma companies by developing and producing these important ingredients for them. The company is known for making chemicals used in medical scans, sweeteners like saccharin, and many other key medicine ingredients, and it supplies these products to more than 400 customers in 39 countries. It has many years of experience and strong skills in making these products. The company focuses on simple, niche, and high-quality work that helps other companies make safe and effective medicines.
What is Blue Jet Healthcare Ltd NSE: BLUEJET?
Blue Jet Healthcare was established in 1968 in Maharashtra, India, and was founded by B.D. Jetwani. It makes chemicals used to make medicines. The company works for other pharma companies by helping them develop and produce important ingredients. It makes chemicals used in medical scanning tests, sweeteners like saccharin, and many ingredients needed to make different medicines. Over the years, it has grown from a small sweetener maker to a well-known company that supplies good-quality products to many big companies around the world through its modern factories in Maharashtra.
Later, the company changed its business direction and became a CDMO, which means Contract Development and Manufacturing Organisation. This simply means the company helps other pharma companies by making the important chemical ingredients needed for medicines. They do not make final medicines themselves. Instead, they make the special chemical parts used to create those medicines. This way of working helped them build strong partnerships with global pharma companies and grow quickly. In 2026, its share price target would be ₹1028, as per stock market analysts.
According to stock market analysts, its share price would be between ₹300 to ₹1028 in 2026.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 300 | 1028 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 411 | 541 |
| फ़रवरी | 352 | 453 |
| मार्च | 320 | 522 |
| अप्रैल | 300 | 585 |
| मई | 326 | 678 |
| जून | 412 | 732 |
| जुलाई | 487 | 774 |
| अगस्त | 521 | 820 |
| सितंबर | 621 | 874 |
| अक्टूबर | 689 | 936 |
| नवंबर | 725 | 978 |
| दिसम्बर | 852 | 1028 |
It has been a leading maker of high-intensity sweeteners for many years. Their most well-known sweetener is saccharin, which has zero calories and is used in many everyday products. It is found in toothpaste, mouthwash, diet drinks, baked foods, and even some medicines. Since saccharin is much sweeter than sugar, only a very small amount is needed, making it cheap and useful. Because it started making saccharin early and always kept the quality high, many food and FMCG companies around the world trust me as a top supplier. In 2027, its share price target would be ₹1960, as per stock market analysts.
Its share price would be between ₹1412 to ₹1960 in 2027, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2027 | 1412 | 1960 |
Another major part of the company’s work is making pharmaceutical intermediates. These are special chemicals used to make many types of medicines. They act like building blocks for drugs that treat cancer, heart problems, infections, and brain disorders. The company uses advanced techniques to make these chemicals safely and with very high purity. Their strong chemical knowledge helps both new drug makers and companies that produce generic medicines. In 2028, its share price target would be ₹2408, as per stock market analysts.
Its share price would be between ₹1860 to ₹2408 in 2028, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2028 | 1860 | 2408 |
It has built a large group of more than 400 customers from 39 countries. These include big pharma companies, major FMCG brands, and global leaders in medical imaging. Their success comes from giving high-quality products, delivering on time, and always following international safety and quality rules. Because many of their clients work in sensitive fields where mistakes can cause big problems, they trust this company for its reliability. In 2029, its share price target would be ₹2857, as per stock market analysts.
Its share price would be between ₹2290 to ₹2857 in 2029, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2029 | 2290 | 2857 |
The company has modern factories in Maharashtra, located in Shahad, Ambernath, and Mahad. These factories have advanced machines, special reactors, testing labs, and strong safety systems to ensure safe and clean production. They follow global standards like WHO-GMP and ISO to maintain high quality. With several factories, the company can produce different products in large amounts without affecting quality. Their plants are designed to handle complex chemical processes, which helps them make special ingredients for medicine, food, and healthcare products for customers worldwide. In 2030, its share price target would be ₹3306, as per stock market analysts.
Its share price would be between ₹2780 to ₹3306 in 2030, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2030 | 2780 | 3306 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 2780 | 2925 |
| फ़रवरी | 2805 | 2984 |
| मार्च | 2832 | 3022 |
| अप्रैल | 2850 | 3056 |
| मई | 2868 | 3078 |
| जून | 2884 | 3090 |
| जुलाई | 2932 | 3135 |
| अगस्त | 2960 | 3157 |
| सितंबर | 2978 | 3174 |
| अक्टूबर | 2990 | 3190 |
| नवंबर | 3025 | 3255 |
| दिसम्बर | 3120 | 3306 |
Research and Development (R&D) is one of the main strengths of the company. The company has advanced labs where skilled scientists work on making new chemical processes, improving existing products, and finding better ways to manufacture complex ingredients. Their R&D team helps them stay updated with global changes and meet the increasing demand for special pharma chemicals. They can also create unique products for clients who need something specific. In 2040, its share price target would be ₹5443, as per stock market analysts.
Its share price would be between ₹4968 to ₹5443 in 2040, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2040 | 4968 | 5443 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 4968 | 5085 |
| फ़रवरी | 4980 | 5123 |
| मार्च | 5011 | 5157 |
| अप्रैल | 5057 | 5184 |
| मई | 5089 | 5210 |
| जून | 5132 | 5235 |
| जुलाई | 5150 | 5257 |
| अगस्त | 5175 | 5275 |
| सितंबर | 5189 | 5321 |
| अक्टूबर | 5210 | 5359 |
| नवंबर | 5256 | 5390 |
| दिसम्बर | 5275 | 5443 |
This company always tries to understand what its customers want. Instead of selling one standard product to everyone, they create special ingredients based on each customer’s needs. This helps customers save time, reduce production costs, and improve product quality. Their flexible working style and willingness to try new solutions make them a preferred partner for many international companies. It ensures customers always receive a reliable supply, steady support, and high-quality products every time. In 2050, its share price target would be ₹7856, as per stock market analysts.
Its share price would be between ₹7344 to ₹7856 in 2050, as per stock market analysts.
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2050 | 7344 | 7856 |
| महीना | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| जनवरी | 7344 | 7490 |
| फ़रवरी | 7387 | 7532 |
| मार्च | 7400 | 7557 |
| अप्रैल | 7432 | 7574 |
| मई | 7450 | 7590 |
| जून | 7475 | 7632 |
| जुलाई | 7490 | 7658 |
| अगस्त | 7511 | 7678 |
| सितंबर | 7534 | 7689 |
| अक्टूबर | 7565 | 7735 |
| नवंबर | 7580 | 7760 |
| दिसम्बर | 7660 | 7856 |
Should I buy Blue Jet Healthcare stock?
| वर्ष | न्यूनतम मूल्य (Rs) | अधिकतम मूल्य (Rs) |
| 2026 | 300 | 1028 |
| 2027 | 1412 | 1960 |
| 2028 | 1860 | 2408 |
| 2029 | 2290 | 2857 |
| 2030 | 2780 | 3306 |
| 2040 | 4968 | 5443 |
| 2050 | 7344 | 7856 |
It could be a good choice for some investors because it makes important products like chemicals for medicines and sweeteners, works with many global clients, and has the potential to grow in the future. Analysts have given positive price targets, showing possible gains. However, the stock also has risks, like recent drops in profits, ups and downs in share price, and reliance on global demand for pharma products. It could be a good choice if you want long-term growth and can handle some risk.
Blue Jet Healthcare earnings results
| मार्च 2020 | मार्च 2021 | मार्च 2022 | मार्च 2023 | मार्च 2024 | मार्च 2025 | टीटीएम | |
| बिक्री + | 538 | 499 | 683 | 721 | 712 | 1,030 | 1,179 |
| व्यय + | 325 | 292 | 434 | 502 | 481 | 652 | 739 |
| परिचालन लाभ | 214 | 207 | 249 | 219 | 231 | 378 | 440 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 37% |
| अन्य आय + | 6 | 9 | 19 | 24 | 18 | 46 | 58 |
| ब्याज | 7 | 5 | 3 | 1 | 0 | 0 | 5 |
| व्याख्या | 18 | 20 | 22 | 25 | 28 | 18 | 21 |
| कर से पहले लाभ | 194 | 190 | 243 | 217 | 220 | 406 | 471 |
| कर | 25% | 26% | 25% | 26% | 26% | 25% | |
| नेट प्रॉफिट + | 145 | 142 | 182 | 160 | 164 | 305 | 352 |
| रुपये में ईपीएस | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 20.33 |
| लाभांश भुगतान % | 0% | 0% | 0% | 0% | 11% | 7% |
कुंजी मीट्रिक
| TTM PE Ratio | PB अनुपात | लाभांश प्राप्ति | सेक्टर PE | सेक्टर PB | सेक्टर Div Yld |
| 26.95 | 8.38 | 0.22% | 36.32 | 5.73 | 0.59% |
Peers & तुलना
| स्टॉक | पीई अनुपात | PB अनुपात | लाभांश प्राप्ति |
| Blue Jet Healthcare Ltd | 31.12 | 8.38 | 0.22% |
| Sun Pharmaceutical Industries Ltd | 38.99 | 5.88 | 0.90% |
| Torrent Pharmaceuticals Ltd | 66.65 | 16.78 | 0.85% |
| Cipla Ltd | 22.84 | 3.85 | 1.07% |
Is Blue Jet Healthcare stock good to buy? (bull case & bear case)
बुल केस:
- In FY2025, its net sales went up from ₹7,116 million in FY2024 to ₹10,300 million.
- Its profit after tax (PAT) increased from ₹1,638 million in FY2024 to ₹3,052 million in FY2025.
- The net profit margin went up from about 23.0% in FY2024 to around 29.6% in FY2025, which means the company is managing costs better and earning more from sales.
- The company works with more than 400 customers in 39 countries, which helps reduce dependence on any single client or market.
- It has three modern factories (Shahad, Ambernath, and Mahad), which help it make more products and meet global demand.
- Its business model as a CDMO and maker of speciality chemicals (contrast-media chemicals, sweeteners, pharma ingredients) makes it a trusted supplier and hard for competitors to replace.
भालू का मामला:
- In Q1 FY26, revenue was ₹354.76 crore, but net profit dropped 17% quarter-on-quarter to ₹91.17 crore.
- The company depends on global demand for pharma ingredients. If demand falls or raw-material costs rise, profits could be lower.
- A large part of the event comes from a few big clients. Losing one of them could reduce overall sales a lot.
- Demand for speciality APIs and contrast-media chemicals may change with global healthcare spending. During economic slowdowns, orders could drop and affect revenue.
निष्कर्ष
It is a global company that makes important chemicals for medicines, like chemicals used in medical scans, sweeteners like saccharin, and other medicine ingredients. It works with many clients in different countries. Over the years, it has grown steadily, improved profits, and built strong relationships with global clients. Although it has good growth potential, it faces risks like changes in global demand, rising raw-material costs, and reliance on major clients. Overall, it is seen as a good stock for long-term investors who can handle some risk.
